TrialSignal
Clinical trial intelligence report
A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02310321
Status
COMPLETED
Phase
PHASE1
Sponsor
Astellas Pharma Inc
Executive brief
Investment-Ready Snapshot
A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia is a PHASE1 clinical asset sponsored by Astellas Pharma Inc in Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia. SEO and diligence focus: Gilteritinib, Idarubicin, Cytarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02310321
Indication
Acute Myeloid Leukemia
Modality
small molecule
Target
Gilteritinib, Idarubicin, Cytarabine
Intervention
Gilteritinib, Idarubicin, Cytarabine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.